DexCom, Inc. (DXCM) Q3 FY2026 earnings

Reported results

• Third quarter 2026 worldwide revenue grew 11% year-over-year to $1.344 billion on a reported basis and 11% on an organic basis.
• GAAP gross profit was $864.4 million or 64.3% of revenue for the third quarter of 2026, compared to $731.4 million or 60.5% of revenue for the third quarter of 2025.
• Non-GAAP gross profit was $875.3 million or 65.1% of reported revenue for the third quarter of 2026, compared to $741.3 million or 61.3% of reported revenue for the third quarter of 2025.
• GAAP operating income for the third quarter of 2026 was $327.2 million or 24.3% of revenue, compared to $242.5 million or 20.1% of revenue for the third quarter of 2025.
• Non-GAAP operating income for the third quarter of 2026 was $339.5 million or 25.3% of reported revenue, compared to $272.9 million or 22.6% of reported revenue for the third quarter of 2025.
• GAAP net income was $275.1 million, or $0.72 per diluted share, and non-GAAP net income was $275.0 million, or $0.73 per diluted share, for the third quarter of 2026.

Guidance

• Fiscal year 2026 Revenue of $5.20 - $5.25 billion (approximately 12-13% growth)
• Fiscal year 2026 Non-GAAP Gross Profit Margin of approximately 64%
• Fiscal year 2026 Non-GAAP Operating Margin of approximately 24%
• Fiscal year 2026 Adjusted EBITDA Margin of approximately 32%

Price and volatility reaction

The stock moved +3.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -10.2 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.